![]() |
|
|
3
,**
Department of Biochemistry,
*
Fels Institute for Cancer Research and Molecular Biology
and Department of Microbiology and Immunology,
**
Temple University School of Medicine, Philadelphia, PA 19140
3To whom correspondence should be addressed. E-mail: dsoprano{at}nimbus.temple.edu.
Retinoids have been demonstrated to have pharmacological application in the areas of dermatology and oncology. In addition to the natural retinoids such as all-trans-retinoic acid and 9-cis-retinoic acid, many new potential retinoid drugs have been synthesized, including retinoic acid receptor (RAR)-subtype selective agonists, retinoid X receptor (RXR)-selective agonists, RAR-selective antagonists, anti-AP1-specific retinoids and retinoids that induce apoptosis. Recent studies demonstrate that some retinoids, in addition to modulating the RAR/RXR pathway, are also capable at pharmacological concentrations of binding to aryl hydrocarbon receptor (AhR) and activating the AhR/AhR nuclear translocator pathway. Future studies are necessary to ascertain the consequences, if any, of activation of the AhR signaling pathway by pharmacological doses of specific retinoids.
KEY WORDS: aryl hydrocarbon receptor AhR nuclear translocator retinoic acid receptor retinoids retinoid X receptor
This article has been cited by other articles:
![]() |
A. C. Ross Advances in Retinoid Research: Mechanisms of Cancer Chemoprevention Symposium Introduction J. Nutr., January 1, 2003; 133(1): 271S - 272. [Full Text] [PDF] |
||||